NCT04618939View on ClinicalTrials.gov

To Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children

PHASE3CompletedINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

October 20, 2016

Primary Completion Date

April 28, 2017

Study Completion Date

April 28, 2017

Conditions
DiphtheriaTetanus
Interventions
BIOLOGICAL

BR-TD-1001

0.5 mL, IM

BIOLOGICAL

Td-pur inj

0.5 mL, IM

Trial Locations (9)

Unknown

Changwon Fatima Hospital, Changwon

The Catholic University of Korea Daejeon St. Mary's Hospital, Daejeon

The Catholic University of Korea Incheon St. Mary's Hospital, Incheon

Asan Medical Center, Seoul

Eulji University Eulji General Hospital, Seoul

Hanil General Hospital, Seoul

Korea Cancer Center Hospital, Seoul

The Catholic University of Korea St. Paul's Hospital, Seoul

Yonsei University Wonju Severance Christian Hospital, Wŏnju

All Listed Sponsors
lead

Boryung Biopharma Co., Ltd.

INDUSTRY

NCT04618939 - To Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children | Biotech Hunter | Biotech Hunter